Maternal Therapy With TAF Versus TDF to Prevent Vertical Transmission of Hepatitis B

UnknownOBSERVATIONAL
Enrollment

450

Participants

Timeline

Start Date

January 27, 2020

Primary Completion Date

September 30, 2021

Study Completion Date

September 30, 2021

Conditions
Hepatitis B, ChronicPregnancy Related
Interventions
DRUG

Tenofovir Alafenamide 25 MG for arm (A)

Tenofovir Alafenamide (TAF) will be provided, 25 mg Per Oral daily.

DRUG

Tenofovir Disoproxil Fumarate 300mg for arm (B)

Tenofovir Disoproxil Fumarate (TDF) will be provided, 300 mg Per Oral daily.

Trial Locations (11)

201508

RECRUITING

Shanghai Public Health Clinical Center, Fudan University, Zhujing

Unknown

RECRUITING

Pingdingshan Hospital of Chongqing Public Health Medical Treatment Center, Shapingba

RECRUITING

First Affiliated Hospital of Fujian Medical University, Fuzhou

RECRUITING

The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen

RECRUITING

Hainan General Hospital, Haikou

RECRUITING

The Third Hospital of Qinhuangdao, Qinhuangdao

RECRUITING

The Fourth Hospital of Harbin Medical University, Harbin

RECRUITING

Xiangya Hospital, Central South University, Changsha

RECRUITING

Ganzhou Fifth People's Hospital, Ganzhou

RECRUITING

Shengjing Hospital of China Medical University, Shenyang

RECRUITING

Yuyao People's Hospital of Zhejiang Province, Yuyao

Sponsors

Lead Sponsor

All Listed Sponsors
lead

New Discovery LLC

INDUSTRY

NCT04211805 - Maternal Therapy With TAF Versus TDF to Prevent Vertical Transmission of Hepatitis B | Biotech Hunter | Biotech Hunter